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Thomas Hodgkin’s and Samuel Wilks ﬁrst recognized Hodgkin disease in the ﬁrst half of the 19th century. Initially described as
lymphogranulomatosis, it was later recognized to be a lymphoid neoplasm derived from B cells and was classiﬁed on the basis of
its histopathological features. Hodgkin lymphomas are now regarded as encompassing two clearly deﬁned entities according to the
WHO classiﬁcation: nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL) and classical Hodgkin Lymphoma (CHL).
This paper focuses on the current knowledge about the biological features that characterize both NLPHL and CHL, highlighting
those relevant to correct pathological diagnosis and those that might be associated with patient outcome.
1.Introduction
Hodgkin’s disease was ﬁrst recognized in the ﬁrst half
of the 19th century by Hodgkin [1]a n dW i l k s[ 2, 3].
Initially described as lymphogranulomatosis, it was later
recognized as being a lymphoid neoplasm derived from
B cells and classiﬁed following the Lukes-Butler scheme
[4, 5] on the basis of its histopathological features. This
pathological classiﬁcation was identiﬁed early on as the
main prognostic marker since the nature of the reactive
inﬁltrate or microenvironment reﬂected the host response
and thus, prognosis [4, 6]. Nowadays Hodgkin’s lymphomas
is regarded as encompassing two clearly deﬁned entities
according to the WHO classiﬁcation: nodular lymphocyte-
predominant Hodgkin lymphoma (NLPHL) and classical
Hodgkin lymphoma (CHL) [7–10]. These two entities diﬀer
in clinical features and behaviour but, more importantly, in
the pathological and biological features of their neoplastic
and microenvironmental compartments.
The diﬀerences in the biological features of the tumours
are routinely used in the pathological diagnosis of patients
with HL [7, 11] but they can also be exploited as biomarkers
of prognosis. This paper focuses on our current knowledge
of the biological features that characterize both NLPHL
and CHL, highlighting those relevant to correct pathological
diagnosis and those that might be associated with patient
outcome.
2. NLPHL: Usefulness of the Microenvironment
inDiagnosis
Nodular lymphocyte-Predominant Hodgkin lymphoma
accounts for approximately 5% of all Hodgkin’s lymphomas.
This type is characterized clinically by a relatively indolent
course, a very good response to standard therapies in cases
with low-stage disease, but an unfavourable prognosis for
advanced stages [9, 12]. Rates of progression to large B
cell lymphoma (commonly Diﬀu s eL a r g eBC e l ll y m p h o m a
(DLBCL), rarely T cell/Histiocyte Rich-like B cell lymphoma
(T/HRBCL)) vary according to the series, with a range
between 3%–12% of cases [12–16].
Biologically, NLPHL is a Germinal Centre-(GC-)derived
B cell neoplasm [17, 18] that retains an almost complete
B Cell program at the transcriptional [19] and phenotypic
[8, 20] levels. The characteristic lymphocyte-Predominant
(LP) cells exhibit a GC phenotypic proﬁle with expression
o fG Cm a r k e r ss u c ha sB C L 6[ 11, 21], GCET1 [22]a n d
LMO2 [23], together with expression of transcription factors
related to a sustained B cell program such as Oct-2 and2 Advances in Hematology
BOB.1. Interestingly, the GC-related proﬁle is seen not only
in LP cells but also in the surrounding T cells, which
characteristically create a rosette-like pattern typical of
NLPHL (Figure 1). These rosetting T cells have a Follicular T
cellphenotypewithexpressionofCD3/CD4/CD57[24],bcl6
[21], PD1 [20, 25] and, interestingly, CXCL13, a chemokine
that is known to induce B cell homing to lymphoid follicles
and that plays a role in the T cell-dependent B cell aﬃnity
maturation process [26]. These observations suggest that
NLPHL is characterized by a GC phenotype in both LP
and T cells. This combination is not found in classical HL
(CHL), with the exception of lymphocyte-Rich CHL. In fact,
this particular subtype of CHL has a proﬁle intermediate
between those of NLPHL and CHL with overexpression of
B cell transcription program markers and the presence of
a follicular T cell background in a substantial proportion
of cases [27]( Figure 1). This is not the case for the other
types of CHL in which the B cell program and the germinal
centre microenvironment are lost. It is remarkable that
this previously described immunohistological pattern (i.e.,
rosettes of Follicular T cells surrounding large B cells) can
also be exploited in the diﬀerential diagnosis of NLPHL and
T/HRBCL, especially in cases whose morphological features
overlap [11, 20, 28].
3. ClassicalHodgkinLymphoma (CHL):
The Microenvironment as
aP r ogno s ticM ark e r
CHL accounts for 95% of all Hodgkin’s lymphomas. This
type is characterized by a relative paucity of Reed-Sternberg
and Hodgkin neoplastic cells in a background of mixed
inﬂammatory inﬁltrate by histiocytes, small lymphocytes,
eosinophils, neutrophils, plasma cells, ﬁbroblasts and col-
lagen. Depending on the particular combinations of these
elementsandthespeciﬁcfeaturesoftheneoplasticcells,cases
may be subclassiﬁed into one of four subtypes: nodular scle-
rosis, mixed cellularity, lymphocyte-rich and lymphocyte-
depleted [7]. Initially consideredthe best predictorof clinical
outcome in CHL [4, 6] histological classiﬁcation per se has
lost its predictive power, mainly due to the considerable
advances in therapeutic regimens [29–31]. These therapeutic
improvements have transformed CHL into a curable dis-
ease in more than 85% of cases. However, a considerable
percentage of patients still fail to respond successfully to
current standard therapies. Early identiﬁcation of these cases
has become the main objective of clinical and biological
research.Intheclinicalﬁeldithasbecomeapparentthatearly
interim 2-[18F]ﬂuoro-2-deoxy-D-glucose positron emission
tomographyisagoodmarkerofprognosisandcouldbeused
for planning risk-adapted treatment in advanced HL [32]. In
the biological ﬁeld, the extensive study of pathways involved
in HL pathogenesis has identiﬁed apoptosis deregulation
and constitutive NFκB activity as being the factors mainly
responsible for tumor unrestricted growth [17, 29, 33]. In
particular, constitutive NFκB signalling has been implicated
intheactivationofupstreamreceptors[34–38]andinseveral
genetic lesions aﬀecting the NFκBp a t h w a y[ 39–45].
Together with genetic lesions aﬀecting the neoplas-
tic population, this malignant component is also tightly
regulated by interactions with the microenvironment. Of
particular interest is the presence of biased T cell populations
in HL cases, evidence for a disregulation of T cell immune
function. In this sense, a considerable fraction of inﬁltrating
CD4+ T cells are regulatory (Treg) cells which have been
shown to display immunosuppressive activity on HL Th2
cells [46]. It has been also shown that together with T regs
(recruited due to the secretion of galectin-1 [47, 48]), PD1+
T cells interact with Hodgkin and R-S cells as outlined in
the previous section [20, 27, 46, 52, 55]. It has been clearly
demonstrated that neoplastic HL cells express PD1-L genes
B7-H1 and B7-DC and this expression is induced by EBV
latent membrane proteins. Blockade of this immunological
synapse leads to restoration of IFNγ production by CD4+ T
cells in the microenvironment of HL cases and to inhibition
of the phophorilation of SHP-2, a mediator of the PD1
signallingpathway.ThustheexpressionofPD1LgenesbyHL
cells may sustain this immunological synapse that leads to
inhibition of IFNγ production by TCD4 cells [52]. Blockade
of this crosstalk leads to the recovery of T cell antitumoral
function thus providing a basis for immunotherapy of HL
[56, 57]( Figure 2).
4.TranslationalBiology inCHL
The knowledge based on the biology of CHL has recently
become of potential clinical application after the generation
of prognostic models of the expression of many of these
biological markers. In two very recent papers [58, 59]
genome-wide analysis of CHL cases was used to identify
gene signatures associated with clinical outcome. These
particular gene signatures were validated in routinely pro-
cessed Formalin-Fixed Paraﬃn-Embedded (FFPE) samples
using RT-PCR [58] or Immunohistochemistry [59], which
are both techniques that could be implemented in clinical
laboratories.
In the study by Sanchez-Espiridion et al. [58]g e n e sw e r e
selected on the basis of previous data published by the same
group [53] who identiﬁed genes involved in the regulation
of mitosis and cell growth/apoptosis (TOP2A, RRM2, PCNa,
MAD2L1 and CDC2), those expressed by the tumoral cells
(as demonstrated by the use of HL cell lines as control),
and genes expressed by the microenvironmental compart-
ment (including those expressed by monocyte/macrophages
STAT1, ALDH1A1) and T cells (SH2D1A). This particular
set of genes was validated by immunohistochemistry in
the same series of patients and has recently been con-
ﬁrmed in a new independent retrospective series of HL
patients using Real-time PCR [58]. Apoptosis-related genes
(BCL2,BCL2L1,CASP3)andcellcycle-associatedtranscripts
(CCNA1, CDC2, CCNA2) are among the markers with
conﬁrmedprognosticvalue,andmayprovidearationalbasis
for the use of new therapeutic agents targeting pathways in
patients with advanced or refractory CHL.
Interestingly, among the pathways associated with worse
outcome in CHL in the study by S´ anchez-Aguilera et al. [53]
monocyte/macrophages prove to be a major determinant ofAdvances in Hematology 3
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Figure 1: NLP-HL: HE section of a case of Nodular lymphocyte-predominant Hodgkin lymphoma, showing a typical lymphocyte-
Predominant (LP) cell positive for CD20 (NLP-CD20) and surrounded by a rim of PD1-positive T cells (NLP-PD1). LR-CHL: HE section of
acaseoflymphocyte-RichClassicalHodgkinlymphomathathighlightsatypicalReed-Sternberg(R-S)cellwiththecharacteristicphenotype
(CD30+, LR-CD30) and surrounded by a rim of PD1-positive T cells (LR-PD1). The pattern is reminiscent of that found in the outer part
of the germinal centre where PD1-positive cells surround large B blasts (see arrows in the immunoﬂuorescence capture region of the outer
zone of a reactive germinal centre).
PD1-L
↓ IFNγ
↑ Galectin 1
IL-10
Th1
TCL
TCL
Treg
Treg
Treg
PD1+ T
PD1+ T
PD1+ T
PD1+ T
Th2
Th2
↑ IL-10
TARC
MDC
(CCL22)
CCL5
↑ CSF-1
PD1+ T
Treg
Treg PD1+ T
STAT1+
TAM
HRS cell
Figure 2: The HRS cell and its cellular microenvironment. Signiﬁcant interactions with impact in patients outcome are depicted. Increased
Galectin1 and IL-10 secreted by HRS (Hodgkin and Reed-Sternberg) cells lead to decreased TCL (T cytotoxic) and Th1 responses, together
with a Treg increase which, in turn, suppresses both Th2 and PD1+ T cell activity [46–51]. PD1+CD4+ T cell activity is additionally
suppressed by direct interations trough PD1-PD1L immunological synapse (T cell exhaustion) [52]. This leads to a decreased IFNγ
production. Additionally, increased TAM (Tumor Associated Macrophages) contribute to T cell deletion trough STAT1 signaling pathway
[53, 54].4 Advances in Hematology
outcome, a ﬁnding conﬁrmed in the series of Steidl et al.
[59]. These authors identiﬁed a gene signature of tumor-
associatedmacrophagesthatwassigniﬁcantlyassociatedwith
primary treatment failure. They validated their ﬁndings
immunohistochemically by quantifying the presence of
C68+ macrophages in diagnostic samples, demonstrating
that the higher the content of macrophages in the biopsy
the greater the risk of progression after primary treatment
and relapse following autologous stem-cell transplantation.
On the other hand, patients with limited-stage disease
and without elevated numbers of CD68+ cells had a
long-term disease-speciﬁc survival of 100% using current
treatment strategies. These data provide further support
for the hypothesis that speciﬁc tumor microenvironmental
components can be used as markers of prognosis in patients
withCHL.Theseresultssuggestsnewpossibilitiesforspeciﬁc
therapies that target these cellular components and could
be used as adjuvant therapy in patients with poor outcome.
Conversely, better identiﬁcation of good outcome patients at
diagnosis could avoid unnecessary overtreatment.
5. Conclusions
The molecular dissection of Hodgkin’s lymphomas using
transcriptional proﬁling and detailed phenotypic analysis
has expanded our view of Hodgkin lymphoma as a disease.
First, it has clariﬁed the current classiﬁcation, establishing
NLPHL as a diﬀerent disease entity from CHL [7]a n d
identifying new markers that can be used in routine practice
for this diﬀerential diagnosis and with other disease entities.
Second, it conﬁrms in a very sophisticated way the pioneer
reports[60–62]thatassignedtospeciﬁcmicroenvironmental
cellular components (i.e., macrophages) a role as biomarkers
ofpatientoutcome,simultaneouslyidentifyingpotentialnew
treatment strategies.
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